Coppell Advisory Solutions »

Lineage Cell Therapeutics In shares owned by Coppell Advisory Solutions

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by Coppell Advisory Solutions from 13F filings

Historical chart of Coppell Advisory Solutions investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by Coppell Advisory Solutions consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by Coppell Advisory Solutions

Quarter filed Position value Share count Share price at filing
2024-09-30 $57 63 0.92
2024-06-30 $63 63 1.00
2023-12-31 $68 63 1.10
2023-09-30 $189 162 1.17
2023-06-30 $132 94 1.40
2022-12-31 $189 162 1.17

More positions owned by Coppell Advisory Solutions

First Tr Exchange Traded Fd Vi Tcw Opportunis Etf Fixd (FIXD)
First Tr Exchange Traded Fd Iv First Tr Enh New Etf FTSM (FTSM)
Tesla Tsla (TSLA)
Kingsmen Resources Ord KNG (KNG)
Walmart WMT (WMT)
Oracle Corp Orcl (ORCL)
Unitedhealth Group Unh (UNH)
Spdr Series Trust Spdr Bloomberg Etf Bil (BIL)
First Tr Exchange Traded Fd Vi Ft Cboe Vest U S Eq Bufer S Bufr (BUFR)
SPDR S&P 500 ETF Trust Spy (SPY)
Etf Series Solutions Aam Lw Dur Pfd Etf PFLD (PFLD)
Ft Cboe Vest Fund Of Deep Buffer Etf Bufd (BUFD)
First Tst Value Li Shs Etf FVD (FVD)
Microsoft Corp MSFT (MSFT)
Apple Aapl (AAPL)

View all positions for Coppell Advisory Solutions

Top funds holding Lineage Cell Therapeutics In

Broadwood Capital
BlackRock
Vanguard Group
Perceptive Advisors
Defender Capital
Raffles Associates
Alyeska Investment Group
Geode Capital Management
State Street Corporation
DAFNA Capital Management
Renaissance Technologies
Northern Trust
Jacobs Levy Equity Management
Jpmorgan Chase & Co
Brian McDonald

View all funds holding Lineage Cell Therapeutics In